Hillers letter on the subject, recently published in Maturitas but not linked from the original review, states that: In light of the recent retraction of Yoshihiro Satos publications due to findings of fraudulent data, I and the editors of Maturitas felt it appropriate to reassess the review I authored (then under the name Peterson) published in 2014 entitled A review of vitamin D and Parkinsons disease, in which Satos publications played a prominent role.[1] Not all Satos papers have been retracted at this time [ nota bene : true, 103 is not all of them], but we feel it necessary to point out which assessments of the evidence contained in the review may have been affected had the publications from Sato not been included
The basis, per the FDA document, was that the nominators of the substance had withdrawn their nominations
The applicant provided eight studies to support these claims, as well as background articles about occurrence and treatment of CDI and rCDI
Inhibitory interneurons regulate temporal precision and correlations in cortical circuits
I was shocked at the response so quickly
Nanotechnology-based drug delivery for central nervous system disorders
